ArriVent BioPharma Advances in Lung Cancer Research, Sets Sights on Future Milestones
NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced positive strides in its first-quarter progress, particularly in the development of firmonertinib, a promising drug for non-small cell lung …
ArriVent BioPharma Advances in Lung Cancer Research, Sets Sights on Future Milestones Read More